Study S002797

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Moderate to Severe Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy

ClinicalTrials.gov record

Registration

Registration: NCT07501832
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 140
Start: 2026-03-27
Primary completion: 2028-09-28
Lead sponsor: Gan & Lee Pharmaceuticals.
Conditions: Obstructive Sleep Apnea (OSA)
Interventions: DRUG:GZR18 injection; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change from baseline in Apnea-Hypopnea Index (AHI) after 52 weeks of treatment [52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.